About the VHIR
Here at the Vall d'Hebron Research Institute (VHIR) we promote biomedical research, innovation and teaching. Over 1,800 people are seeking to understand diseases today so the treatment can be improved tomorrow.
Research
We are working to understand diseases, to find out how they operate and to create better treatments for patients. Get to know about our groups and their lines of research.
People
People are the centre of the Vall d'Hebron Research Institute (VHIR). This is why we are bound by the principles of freedom of research, gender equality and professional attitudes that HRS4R promotes.
Clinical trials
Our work is not just basic or translational; we are leaders in clinical research. Enter and find about the clinical trials we are conducting and why we are a world reference in this field.
Progress
Our aim is to make the research carried out at the Vall d’Hebron Research Institute (VHIR) a driving force for transformation. How? By identifying new channels and solutions for the promotion of people's health and well-being.
Core facilities
We offer specialist support for researchers, internal and external alike, ranging from specific services to preparing complete projects. All this, from a perspective of quality and speed of response.
News
We offer you a gateway for staying up to date on everything going on at the Vall d’Hebron Research Institute (VHIR), from the latest news to future solidarity activities and initiatives that we are organising.
The group of Clinical Neuroimmunology - Centre d'Esclerosi Múltiple de Catalunya (Cemcat) at the Vall d'Hebron Institut de Recerca (VHIR) is a multidisciplinary group dedicated to clinical assistance, physical and cognitive rehabilitation, and clinical and basic research on multiple sclerosis (MS). Cemcat is a national but also an international reference center in the clinical assistance of MS patients. The research performed in the group is divided and further combined in clinical and basic research. In addition, basic research has a marked translational character since the ultimate goal of the group is to improve the quality of life of patients suffering from MS, through in-depth knowledge of the pathogenic mechanisms of the disease and the development of new and more effective therapeutic approaches.
PMID: 35001198 Journal: JOURNAL OF NEUROLOGY Year: 2022 Reference: J Neurol. 2022 Apr;269(4):1764-1772. doi: 10.1007/s00415-021-10958-z. Epub 2022 Jan 10. Impact factor: 4.849 Publication type: Paper in international publication Authors: Cobo-Calvo, Alvaro, Zabalza, Ana, Rio, Jordi, Arrambide, Georgina, Otero-Romero, Susana, Tagliani, Paula, Cardenas-Robledo, Simon, Castillo, Mireia, Espejo, Carmen, Rodriguez, Marta et al. DOI: 10.1007/s00415-021-10958-z
PMID: 34994577 Journal: Multiple Sclerosis Journal Year: 2022 Reference: Mult Scler. 2022 Jun;28(7):1131-1137. doi: 10.1177/13524585211061343. Epub 2022 Jan 7. Impact factor: 6.312 Publication type: Paper in international publication Authors: Hyland, Megan, Mowry, Ellen M, Naismith, Robert, Naylor, Maria L, Nicholas, Jacqueline, Rajbhandar, Rajani, Singh, Carol M, Tintore, Mar, Zabalza, Ana, Ziemssen, Tjalf et al. DOI: 10.1177/13524585211061343
PMID: 34800172 Journal: JOURNAL OF NEUROLOGY Year: 2022 Reference: J Neurol. 2022 Jan;269(1):460. doi: 10.1007/s00415-021-10906-x. Impact factor: 4.849 Publication type: Letter or abstract Authors: Zabalza, Ana, Castillo, Joaquim, Arrambide, Georgina, Nos, Carlos, Cobo-Calvo, Alvaro, Tur, Carmen, Auger, Cristina, Sastre-Garriga, Jaume, Montalban, Xavier, Rodriguez-Acevedo, Breogan et al. DOI: 10.1007/s00415-021-10906-x
In total, different projects of six research groups will be promoted, focusing on precision medicine and advanced therapies.
Dr. Carmen Espejo and Dr. Georgina Arrambide, researchers at Cemcat and Vall d'Hebron Research Institute, are the first authors of the article.
The research findings propose to modify the McDonald 2017 criteria, only in those in whom diagnosis using the current criteria is not possible.
Simoa HD1 equipment
We are looking for 100 healthy volunteers aged 18 or over to participate in a project where the usefulness of biomarkers in serum will be evaluated to predict the prognosis of the disease and the response to treatments.
